ClinicalTrials.gg
CompletedNCT05885854Updated Jun 2, 2023

XTR003 PET Radiotracer for the Detection of Viable Myocardium

A Phase 2 interventional study of XTR003 in Ischemic Heart Disease (IHD), sponsored by Sinotau Pharmaceutical Group. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-02.

Sponsored by Sinotau Pharmaceutical Group · Phase 2, Interventional, and Diagnostic

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Dec 2021, registered Dec 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Myocardial Ischemia with a site in China — 20 open to participants now, 22 under way, none of them phase 3. Myocardial Ischemia · China.

Enrollment
39th of 48
51 · median 303
Started
2021
with 6 others
Phase 2
2 of 81
1 open now
Registered
59th of 81
by date

Among the 81 studies in Myocardial Ischemia with a site in China, this one is the 39th largest by enrollment of the 48 interventional ones that give a count, is one of 7 that started in 2021, is one of 2 in phase 2, and was the 59th registered.

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

Browse Myocardial Ischemia studies →

Open to participants now

20 of the 81 studies in Myocardial Ischemia with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Myocardial Ischemia with a site in China, or all of them as a file.
02

Study summary

The study was designed to explore the clinical feasibility of XTR003, a PET myocardial fatty-acid tracer, for the detection of viable myocardium in patients with ischemic heart disease (IHD).

Read the detailed description

The incidence of IHD is increasing in China and globally. However, the 18F-FDG-PET patient preparation protocols present challenges in certain patients such as patients with type I and II Diabetes Mellitus. XTR003 is a PET fatty-acid analog used in the imaging of myocardial fatty-acid metabolism. The combination of fasting XTR003/18F-FDG PET imaging may overcome the shortness of glucose-loaded 18F-FDG PET imaging protocol and effectively identify viable myocardium.

This is an exploratory, single-arm, open-label, phase II clinical study with the following objectives:

  1. To explore the clinical feasibility of XTR003 for the detection of viable myocardium in patients with NSTEMI, old myocardial infarction, or total occlusions of coronary arteries.
  2. To evaluate the safety and adverse events incidence of XTR003 in patients with known IHD.
  3. To evaluate the sensitivity and specificity of fasting 18F-FDG/XTR003 PET combining imaging in detecting viable myocardium.
03

Conditions studied

  • Ischemic Heart Disease (IHD)

Keywords

  • Coronary Artery Disease (CAD)
  • Positron Emission Tomography (PET)
  • XTR003 PET myocardial fatty-acid tracer
  • 18F-Fluorodeoxyglucose (18F-FDG)
  • Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)
  • Old Myocardial Infarction (OMI)
  • Total Coronary Occlusions (TCO)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-80 years old men and women.
  2. The diagnosis and assessment of the disease meet any of the following criteria:

    (a) Patients who meet the diagnostic criteria for NSTEMI are stable and require further imaging. (b) Patients with old myocardial infarction confirmed by medical history or imaging examination and now in the stable stage. (c) Patients diagnosed with total coronary occlusions based on coronary angiography showing anterior flow occlusion segment with TIMI grade 0 or coronary CTA examination showing complete coronary artery occlusion.

  3. The rest 99mTc-Sestamibi (MIBI) SPECT imaging has been completed in the past month and no imaging technical issues were leading to poor image quality. Image indicated myocardial perfusion defect of ≥ 2 segments or total resting perfusion score (SRS) ≥4.
  4. The patient has completed glucose-loaded 18F-FDG myocardial metabolic PET imaging in the last month and has not failed to diagnose because of poor image quality due to technical problems with the imaging, except for his own glucose regulation.
  5. Patients who can communicate properly with the investigators, understand and follow the study requirements, voluntarily participate, and understand and sign the .

Exclusion criteria

Exclusion Criteria:

  1. Patients with other preexisting cardiovascular diseases including but not limited to dilated or hypertrophic cardiomyopathy, pericarditis, aortic dissection, uncontrolled severe arrhythmias, and congenital heart disease are deemed not eligible for the study by the principal investigator.
  2. Patients with severe acute or chronic lung disease, including but not limited to , asthma, bronchiectasis, emphysema, pulmonary fibrosis, pulmonary embolism, pneumonia, etc., are deemed not eligible for the study by the principal investigator.
  3. Patients with severe or unstable central nervous system diseases, including but not limited to unstable cerebrovascular diseases, active epilepsy, infectious diseases of the central nervous system, and central nervous system, and central nervous system disease associated with neuropathy or limb movement disorders are deemed not eligible for the study by the principal investigator.
  4. Patients with severe hemorrhagic diseases or coagulation disorders, including but not limited to purpura, hemophilia, and deficiency in vitamin K are deemed not eligible for the study by the principal investigator.
  5. Patients with fever or active infectious diseases are deemed not eligible for the study by the principal investigator.
  6. Patients with serious disorders of organ systems other than those described above and who are deemed not eligible for the study by the principal investigator.
  7. Hematologic antigen/antibody test meets either of the following criteria: anti- antibody (+) and syphilis antibody (+) are deemed not eligible for the study by the principal investigator.
  8. Significant occupational exposure to or treatment with ionizing radiation (e.g., more than 50 mSv/yr) within 10 years.
  9. Pregnant or lactating women.
  10. People with mental disorders or poor compliance.
  11. Men and women of reproductive age refused to adopt plans during the study period and for 6 months after the study ended.
  12. Other circumstances that the investigator considers inappropriate for participating in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    XTR003; At rest

    1. Injection with XTR003 to investigate myocardial fatty-acid metabolism in patients with known IHD. 2. Adjunct injection with 18F-FDG to investigate and trace myocardial glucose metabolism in patients with known IHD. The study population consisted of 50 participants from the following category of patients: (1) Patients with Non-ST elevation myocardial infarction (NSTEMI) (2) Patients with old myocardial infarction (3) Patients with total occlusions of coronary arteries.

    Drug: XTR003

Interventions

  • DrugXTR003

    Enrolled subjects were required to fast for ≥ 6 hours before drug administration at rest; 1. Initial intravenous injection of 18F-FDG to each subject with a dose range of 2.0-3.0 mCi (74-111 MBq). Each patient will be imaged with PET for 10 minutes at 50-70 minutes after the injection. 2. In few minutes, a single intravenous bolus injection of XTR003 will follow and administer to each patient with a dose range of 6.0-8.0 mCi (222-296 MBq). Each patient will be immediately imaged with PET for 15 minutes.

06

What researchers measure

Primary outcomes

  1. To investigate the sensitivity of combining XTR003/FDG PET imaging

    To simultaneously trace fatty-acid and glucose metabolisms for the detection of viable myocardium in IHD patients with NSTEMI, old myocardial infarction, or total occlusions of coronary arteries.

    Time frame: Day 1

  2. To investigate the specificity of combining XTR003/FDG PET imaging

    To simultaneously trace fatty-acid and glucose metabolisms for the detection of viable myocardium in IHD patients with NSTEMI, old myocardial infarction, or total occlusions of coronary arteries.

    Time frame: Day 1

Secondary outcomes

  1. Number of study participants with treatment-related adverse events as determined by safety parameter changes according to CTCAE v5.0

    Safety parameters included adverse events, vital signs (body temperature, blood pressure, respiration rate, pulse rate), physical examinations, laboratory tests (serum cardiac biomarkers, cardiac troponin I, serum biochemistry, haematology, and urinalysis) and electrocardiograms.

    Time frame: Up to 9 days

07

Study locations

1 site
  • TEDA International Cardiovascular Hospital
    Tianjin, Tianjin 300456, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Mar 2023, 14 months.

Of 16 phase 2 interventional studies under Myocardial Ischemia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2022
First posted
Jun 2, 2023
StartActual
Dec 15, 2021
Primary completionActual
Mar 4, 2023
CompletionActual
Mar 5, 2023
Last update
Jun 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05885854
Lead sponsor
Sinotau Pharmaceutical Group
Responsible party
Sponsor
First posted
Jun 2, 2023
Start date
Dec 15, 2021
Primary completion
Mar 4, 2023
Completion
Mar 5, 2023
Last update
Jun 2, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion